Name: ML390
Price: 254.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    IC50: 0.56 μMML390 is a human DHODH inhibitor.Homeobox (Hox) transcription factors are reported to be involved in the hematopoietic differentiation. Recently studies have showed that the inhibitors of dihydroorotate dehydrogenase (DHODH) can induce the differentiation in multiple AML models in vitro and in vivo. More importantly, DHODH inhibitors have been found to be effective at prolonging survival in animal models of leukemia.In vitro: In the screening study, ML390 was identified as the most potent compound against the engineered ERHOX-GFP cell line. Moreover, the addition of uridine to the cell culture media could abrogate the differentiation effects of ML390, demonstrating further evidences that ML390’ effects were due to their inhibition of DHODH-catalyzed pyrimidine synthesis. In addition, ML390 was found to be not able to inhibit DHODH in the P. falciparum parasite, which is the causative agent of malaria. Furthermore, the X-ray structure indicated that the binding of ML390 to the enzyme might be increased by modifying ML390 with a ring in its central portion to lock the molecule into its binding conformation with the amide substituents [1]. In vivo: So far, there is no animal in vivo data reported. Clinical trial: Up to now, ML390 is still in the preclinical development stage.
- Properties
  - Alternative Name
    
    (R)-N-(3-oxo-3-((1,2,3,4-tetrahydronaphthalen-1-yl)amino)propyl)-4-(trifluoromethoxy)benzamide
    
    CAS Number
    
    2029049-79-2
    
    Molecular Formula
    
    C21H21F3N2O3
    
    Molecular Weight
    
    406.4
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    ≥40.6 mg/mL in DMSO; insoluble in H2O; ≥17.47 mg/mL in EtOH
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

ML390

ML390

Background

We Also Recommend

3,4-DAA

GDC-0084